Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption
Open accessAbstract
Current antiangiogenic therapy is limited by its cytostatic nature and systemic side effects. To address these limitations, we have unveiled the role of RhoJ, an endothelial-enriched Rho GTPase, during tumor progression. RhoJ blockade provides a double assault on tumor vessels by both inhibiting tumor angiogenesis and disrupting the preformed tumor vessels through the activation of the RhoA-ROCK (Rho kinase) signaling pathway in tumor endothelial cells, consequently resulting in a functional failure of tumor vasculatures. Moreover, enhanced anticancer effects were observed when RhoJ blockade was employed in concert with a cytotoxic chemotherapeutic agent, angiogenesis-inhibiting agent, or vascular-disrupting agent. These results identify RhoJ blockade as a selective and effective therapeutic strategy for targeting tumor vasculature with minimal side effects.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The RHOJ gene encodes one of many small proteins of the Rho family that bind GTP.
“Gen RHOJ encodes one of many small proteins of the Rho family that bind GTP (guanosine-5′-triphosphate), which acts as an energy transporter in the cell.”
From Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature) (2021) · cites this paper as [190]
Rho proteins regulate the dynamic assembly of cytoskeleton components in several physiological processes, such as cell proliferation and motility.
“Rho proteins regulate the dynamic assembly of cytoskeleton components in several physiological processes, such as cell proliferation and motility.”
From Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature) (2021) · cites this paper as [190]
The protein encoded by the RHOJ gene is activated by vascular endothelial growth factor and can regulate angiogenesis, adipocyte differentiation, endothelial motility, and cytoskeletal formation.
“The protein encoded by the RHOJ gene is activated by vascular endothelial growth factor and can regulate angiogenesis and also plays an important role in adipocyte differentiation, endothelial motility, and cytoskeletal formation [190].”
From Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature) (2021) · cites this paper as [190]
Rho proteins are involved in cancer transformation and metastasis.
“Rho are also involved in cancer transformation and metastasis.”
From Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature) (2021) · cites this paper as [190]
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885 · see citing works
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · see citing works
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 2× · see citing works
“In addition, although it requires further investigation in clinics, several preclinical studies suggested that tumor cells could convert to a more aggressive phenotype with increased invasion and metastasis after the AIA treatment (Bergers and Hanahan, 2008; Casanovas et al., 2005; Ebos and Kerbel, 2011).”
BackgroundAngiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · see citing works
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 6× · see citing works
“Additionally, tumor cells in the intratumoral core have an intrinsic resistance to chemotherapy because they proliferate slowly and the growth fraction is small (Trédan et al., 2007).”
BackgroundInfluentialVEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673 · see citing works
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621 · see citing works
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis
Wang, Y., Nakayama, M., Pitulescu, M. E., Schmidt, T., Bochenek, M. L., Sakakibara, A., Adams, S., Davy, A., Deutsch, U., Lüthi, U., et al. (2010) · Nature · doi:10.1038/nature09002 · Cited by 1,276 · see citing works
Self-citationClinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004 · see citing works
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 991 · see citing works
Disrupting tumour blood vessels
Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1628 · Cited by 931 · see citing works
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · see citing works
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R. B., Norberg, S. M., O’Brien, S., Sennino, B., Nakahara, T., Yao, V., Inai, T., Brooks, P. C., Freimark, B. D., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 814 · see citing works
Targeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2868 · Cited by 751 · see citing works
Self-citationTumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Fukumura, D., & Jain, R. K. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.003 · Cited by 699 · see citing works
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685 · see citing works
Siemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611 · see citing works
Adverse effects of anticancer agents that target the VEGF pathway
Chen, H. X., & Cleck, J. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.94 · Cited by 560 · see citing works
Significance of blood vessel leakiness in cancer.
McDonald, D. M., & Bałuk, P. (2002) · PubMed · Cited by 462 · see citing works
Wachsberger, P. R., Burd, R., & Dicker, A. P. (2003) · PubMed · Cited by 350 · see citing works
Masiero, M., Simões, F. C., Han, H. D., Snell, C. E., Peterkin, T., Bridges, E., Mangala, L. S., Wu, S. Y., Pradeep, S., Li, D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.004 · Cited by 315 · see citing works
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3366 · Cited by 265 · see citing works
Horsman, M. R., & Siemann, D. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2848 · Cited by 248 · see citing works
Fukushima, Y., Okada, M., Kataoka, H., Hirashima, M., Yoshida, Y., Mann, F., Gomi, F., Nishida, K., Nishikawa, S., & Uemura, A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44900 · Cited by 207 · see citing works
Self-citationAngiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy
Gerald, D., Chintharlapalli, S. R., Augustin, H. G., & Benjamin, L. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4697 · Cited by 202 · see citing works
Driving Rho GTPase activity in endothelial cells regulates barrier integrity
Beckers, C., van Hinsbergh, V. W. M., & Amerongen, G. P. V. N. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-06-0403 · Cited by 202 · see citing works
Rho and ROCK Signaling in VEGF‐Induced Microvascular Endothelial Hyperpermeability
Sun, H., Breslin, J. W., Zhu, J., Yuan, S. Y., & Wu, M. H. (2006) · Microcirculation · doi:10.1080/10739680600556944 · Cited by 171 · see citing works
What tangled webs they weave: Rho-GTPase control of angiogenesis
Bryan, B. A., & D'Amore, P. A. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7008-z · Cited by 167 · see citing works
Koh, Y. J., Kim, H.-Z., Hwang, S.-I., Lee, J. E., Oh, N., Jung, K., Kim, M., Kim, K. E., Kim, H., Lim, N. K., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.001 · Cited by 154 · see citing works
Self-citationBono, F., Smet, F. D., Herbert, C., Bock, K. D., Γεωργιάδου, Μ., Fons, P., Tjwa, M., Alcouffe, C., Ny, A., Bianciotto, M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.019 · Cited by 146 · see citing works
Coupling receptor tyrosine kinases to Rho GTPases—GEFs what's the link
Schiller, M. R. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.01.022 · Cited by 145 · see citing works
Tvorogov, D., Anisimov, A., Zheng, W., Leppänen, V., Tammela, T., Laurinavičius, S., Holnthoner, W., Heloterä, H., Holopainen, T., Jeltsch, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.001 · Cited by 135 · see citing works
Small GTPase R-Ras Regulates Integrity and Functionality of Tumor Blood Vessels
Sawada, J., Urakami, T., Li, F., Urakami, A., Zhu, W., Fukuda, M., Li, D. Y., Ruoslahti, E. I., & Komatsu, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.013 · Cited by 109 · see citing works
ED-B fibronectin as a target for antibody-based cancer treatments
Menrad, A., & Menssen, H. D. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.491 · Cited by 102 · see citing works
Yuan, L., Sacharidou, A., Stratman, A. N., Bras, A. L., Zwiers, P. J., Spokes, K., Bhasin, M., Shih, S., Nagy, J. A., Molema, G., et al. (2011) · Blood · doi:10.1182/blood-2010-10-315275 · Cited by 82 · see citing works
The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy
van der Meel, R., Symons, M. H., Kudernatsch, R., Kok, R. J., Schiffelers, R. M., Storm, G., Gallagher, W. M., & Byrne, A. T. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.01.005 · Cited by 73 · see citing works
Kaur, S., Leszczyńska, K. B., Abraham, S., Scarcia, M., Hiltbrunner, S., Marshall, C. J., Mavria, G., Bicknell, R., & Heath, V. L. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.216341 · Cited by 69 · see citing works
Kim, S., Kim, D., Jung, H.-H., Lee, I.-H., Kim, J., Suh, J., & Jon, S. (2012) · Angewandte Chemie · doi:10.1002/anie.201107894 · Cited by 68 · see citing works
Self-citationGenome-wide identification of endothelial cell–enriched genes in the mouse embryo
Takase, H., Matsumoto, K., Yamadera, R., Kubota, Y., Otsu, A., Suzuki, R., Ishitobi, H., Mochizuki, H., Kojima, T., Takano, S., et al. (2012) · Blood · doi:10.1182/blood-2011-12-398156 · Cited by 67 · see citing works
Joo, H. J., Choi, D. K., Lim, J. S., Park, J., Lee, S. H., Song, S., Shin, J. H., Lim, D., Kim, I., Hwang, K.-C., et al. (2012) · Blood · doi:10.1182/blood-2012-04-421610 · Cited by 53 · see citing works
Self-citationThe role of RhoJ in endothelial cell biology and angiogenesis
Leszczyńska, K. B., Kaur, S., Wilson, E., Bicknell, R., & Heath, V. L. (2011) · Biochemical Society Transactions · doi:10.1042/bst20110702 · Cited by 37 · see citing works
Anticancer potential of tumor vascular disrupting agents: review of the latest clinical evidence
Baguley, B. C., & McKeage, M. J. (2012) · Clinical Investigation · doi:10.4155/cli.12.98 · Cited by 10 · see citing works
Einkommen und Unterhalt in Kiel von 1914 bis 1922
Schütz, F. (1923) · Journal of Molecular Medicine · doi:10.1007/bf01716236 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z., Chen, H., Zheng, L., Sun, L., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,387 · see citing works
Rho GTPase signalling in cell migration
Ridley, A. J. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.08.005 · Cited by 779 · see citing works
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 700 · see citing works
Self-citationSmolarz, B., Szyłło, K., & Romanowicz, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910554 · Cited by 560 · see citing works
Park, J.-S., Kim, I.-K., Han, S., Park, I., Kim, C., Bae, J., Oh, S. J., Lee, S., Kim, J. H., Woo, D.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.018 · Cited by 327 · see citing works
Self-citationSTING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
Yang, H., Lee, W. S., Kong, S. J., Kim, C. G., Kim, J. H., Chang, S. K., Kim, S., Kim, G., Chon, H. J., & Kim, C. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125413 · Cited by 311 · see citing works
Self-citationRole of glutamine synthetase in angiogenesis beyond glutamine synthesis
Eelen, G., Dubois, C., Cantelmo, A. R., Goveia, J., Brüning, U., DeRan, M., Jarugumilli, G., van Rijssel, J., Saladino, G., Comitani, F., et al. (2018) · Nature · doi:10.1038/s41586-018-0466-7 · Cited by 220 · see citing works
RHOJ controls EMT-associated resistance to chemotherapy
Debaugnies, M., Rodríguez‐Acebes, S., Blondeau, J., Parent, M.-A., Zocco, M., Song, Y., Maertelaer, V. D., Moers, V., Latil, M., Dubois, C., et al. (2023) · Nature · doi:10.1038/s41586-023-05838-7 · Cited by 207 · see citing works
Self-citationBlocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth
Pérez‐Pérez, M., Priego, E., Bueno, O., Martins, M. S., Canela, M., & Liekens, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00463 · Cited by 187 · see citing works
Rho GTPases modulate malignant transformation of tumor cells
Orgaz, J. L., Herráiz, C., & Sanz‐Moreno, V. (2014) · Small GTPases · doi:10.4161/sgtp.29019 · Cited by 177 · see citing works
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164 · see citing works
Chon, H. J., Lee, W. S., Yang, H., Kong, S. J., Lee, N. K., Moon, E. S., Choi, J., Han, E. C., Kim, J. H., Ahn, J. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1932 · Cited by 158 · see citing works
Self-citationImpaired angiopoietin/Tie2 signaling compromises Schlemm’s canal integrity and induces glaucoma
Kim, J., Park, D. Y., Bae, H., Park, D. Y., Kim, D., Lee, C., Song, S., Chung, T.-Y., Lim, D. H., Kubota, Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94668 · Cited by 138 · see citing works
Self-citationPancreatic adenocarcinomas with mature blood vessels have better overall survival
Katsuta, E., Qi, Q., Peng, X., Hochwald, S. N., Yan, L., & Takabe, K. (2019) · Scientific Reports · doi:10.1038/s41598-018-37909-5 · Cited by 131 · see citing works
Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis
Mashreghi, M., Azarpara, H., Bazaz, M. R., Jafari, A., Masoudifar, A., Mirzaei, H., & Jaafari, M. R. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26049 · Cited by 129 · see citing works
Liu, D., Chang, C., Lü, N., Wang, X., Lu, Q., Ren, X., Ren, P., Zhao, D., Wang, L., Zhu, Y., et al. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00604 · Cited by 120 · see citing works
Vascular Normalization: A New Window Opened for Cancer Therapies
Yang, T., Xiao, H., Liu, X., Wang, Z., Zhang, Q., Wei, N., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719836 · Cited by 121 · see citing works
Lee, S. J., Yang, H., Kim, W. R., Lee, Y. S., Lee, W. S., Kong, S. J., Lee, H. J., Kim, J. H., Cheon, J., Kang, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002195 · Cited by 118 · see citing works
Self-citationThe development of site-specific drug delivery nanocarriers based on receptor mediation
Wang, X., Li, S., Shi, Y., Chuan, X., Li, J., Zhong, T., Zhang, H., Dai, W., He, B., & Zhang, Q. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.028 · Cited by 113 · see citing works
Rho-Associated Coiled-Coil Kinase (ROCK) in Molecular Regulation of Angiogenesis
Liu, J., Wada, Y., Katsura, M., Tozawa, H., Erwin, N. A., Kapron, C. M., Bao, G., & Liu, J. (2018) · Theranostics · doi:10.7150/thno.30305 · Cited by 113 · see citing works
Hong, S., Zheng, D., Zhang, C., Huang, Q., Cheng, S., & Zhang, X. (2020) · Science Advances · doi:10.1126/sciadv.abb0020 · Cited by 106 · see citing works
Baicalein: A metabolite with promising antineoplastic activity
Tuli, H. S., Aggarwal, V., Kaur, J., Aggarwal, D., Parashar, G., Parashar, N. C., Tuorkey, M. J., Kaur, G., Savla, R., Sak, K., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118183 · Cited by 101 · see citing works
Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization
Xu, Z., Guo, C., Ye, Q., Shi, Y., Sun, Y., Zhang, J., Huang, J., Huang, Y., Zeng, C., Zhang, X. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26697-8 · Cited by 100 · see citing works
Diosmetin inhibits tumor development and block tumor angiogenesis in skin cancer
Choi, J., Lee, D.-H., Park, S., & Seol, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109091 · Cited by 85 · see citing works
Self-citationAnti-angiogenesis in cancer therapeutics: the magic bullet
Oguntade, A. S., Al-Amodi, F., Alrumayh, A., Alobaida, M., & Bwalya, M. (2021) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-021-00072-6 · Cited by 82 · see citing works
Metabolic Signatures of Distinct Endothelial Phenotypes
Dumas, S. J., García‐Caballero, M., & Carmeliet, P. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.05.009 · Cited by 80 · see citing works
Intracellular endothelial cell metabolism in vascular function and dysfunction
Citrin, K. M., Chaube, B., Fernandez-Hernando, C. F., & Suárez, Y. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.11.004 · Cited by 76 · see citing works
Chin, V. T., Nagrial, A. M., Chou, A. S. Y., Biankin, A. V., Gill, A. J., Timpson, P., & Pajic, M. (2015) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2015.17 · Cited by 71 · see citing works
ARHGAP18: an endogenous inhibitor of angiogenesis, limiting tip formation and stabilizing junctions
Chang, G., Lay, A. J., Ting, K. K., Zhao, Y., Coleman, P. R., Powter, E. E., Formaz‐Preston, A., Jolly, C. J., Bower, N. I., Hogan, B. M., et al. (2014) · Small GTPases · doi:10.4161/21541248.2014.975002 · Cited by 70 · see citing works
Piezo2 protein: A novel regulator of tumor angiogenesis and hyperpermeability
Yang, H., Liu, C., Zhou, R., Yao, J., Li, X., Shen, Y., Cheng, H., Yuan, J., Yan, B., & Jiang, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.10134 · Cited by 66 · see citing works
Self-citationLee, Y. S., Lee, W. S., Kim, C. W., Lee, S. J., Yang, H. J., Kong, S. J., Ning, J., Kang, B., Kang, B., Kim, W. R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000857 · Cited by 62 · see citing works
Self-citationTumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery
Kim, S. J., Jung, K. H., Son, M. K., Park, J. H., YAN, H. H., Fang, Z., Kang, Y. W., Han, B., Lim, J. H., & Hong, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.035 · Cited by 58 · see citing works
Self-citationPajic, M., Herrmann, D., Vennin, C., Conway, J. R. W., Chin, V. T., Johnsson, A., Welch, H. C. E., & Timpson, P. (2015) · Small GTPases · doi:10.4161/21541248.2014.973749 · Cited by 56 · see citing works
RhoJ interacts with the GIT-PIX complex and regulates focal adhesion disassembly
Wilson, E., Leszczyńska, K. B., Poulter, N. S., Edelmann, F., Salisbury, V. A., Noy, P. J., Bacon, A., Rappoport, J. Z., Heath, J. K., Bicknell, R., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.140434 · Cited by 55 · see citing works
Kim, C. W., Chon, H. J., & Kim, C. (2021) · Cancers · doi:10.3390/cancers13194906 · Cited by 55 · see citing works
Self-citationRho-Family Small GTPases: From Highly Polarized Sensory Neurons to Cancer Cells
Ueyama, T. (2019) · Cells · doi:10.3390/cells8020092 · Cited by 46 · see citing works
Lu, H., Yuan, P., Ma, X., Jiang, X., Liu, S., Ma, C., Philipsen, S., Zhang, Q., Yang, J., Xu, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36409-z · Cited by 45 · see citing works
Analysis of Body-wide Unfractionated Tissue Data to Identify a Core Human Endothelial Transcriptome
Butler, L. M., Hallström, B. M., Fagerberg, L., Pontén, F., Uhlén, M., Renné, T., & Odeberg, J. (2016) · Cell Systems · doi:10.1016/j.cels.2016.08.001 · Cited by 43 · see citing works
Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin
Shen, Y., Li, S., Wang, X., Wang, M., Tian, Q., Yang, J., Wang, B., Wang, B., Liu, P., & Yang, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1366-x · Cited by 44 · see citing works
Targeted delivery of nano-radiosensitizers for tumor radiotherapy
Shi, S., Zhong, H., Zhang, Y., & Mei, Q. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216101 · Cited by 44 · see citing works
Qiao, D., Xing, J., Duan, Y., Wang, S., Yao, G., Zhang, S., Jin, J., Lin, Z., Chen, L., & Piao, Y. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154046 · Cited by 41 · see citing works
Actin cytoskeleton in angiogenesis
Nair, N., Samuel, V., Ramesh, L., Marib, A., David, D. T., & Sundararaman, A. (2022) · Biology Open · doi:10.1242/bio.058899 · Cited by 42 · see citing works
Liu, R., Cheng, Y., Yu, J., Lv, Q., & Zhou, H. (2015) · Gene · doi:10.1016/j.gene.2015.03.008 · Cited by 41 · see citing works
Ma, Z., Sun, Q., Zhang, C., Zheng, Q., Liu, Y., Xu, H., He, Y., Yao, C., Chen, J., & Xia, H. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81972 · Cited by 40 · see citing works
Wang, M., Zhang, C., Zheng, Q., Ma, Z., Qi, M., Di, G., Ling, S., Xu, H., Qi, B., Yao, C., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65653 · Cited by 40 · see citing works
RhoJ Regulates α5β1 Integrin Trafficking to Control Fibronectin Remodeling during Angiogenesis
Sundararaman, A., Fukushima, Y., Norman, J. C., Uemura, A., & Mellor, H. (2020) · Current Biology · doi:10.1016/j.cub.2020.03.042 · Cited by 39 · see citing works
Self-citationLiu, S., Li, H., Xia, L., Xu, P., Ding, Y., Huo, D., & Hu, Y. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.06.036 · Cited by 38 · see citing works
Building Blood Vessels—One Rho GTPase at a Time
Barlow, H. R., & Cleaver, O. B. (2019) · Cells · doi:10.3390/cells8060545 · Cited by 36 · see citing works
Baicalein inhibits tumor progression by inhibiting tumor cell growth and tumor angiogenesis
Park, Y.-G., Choi, J., Jung, H.-K., Kim, B., Kim, C., Park, S., & Seol, J.-W. (2017) · Oncology Reports · doi:10.3892/or.2017.6007 · Cited by 35 · see citing works
Self-citationRhoJ integrates attractive and repulsive cues in directional migration of endothelial cells
Fukushima, Y., Nishiyama, K., Kataoka, H., Fruttiger, M., Fukuhara, S., Nishida, K., Mochizuki, N., Kurihara, H., Nishikawa, S., & Uemura, A. (2020) · The EMBO Journal · doi:10.15252/embj.2019102930 · Cited by 32 · see citing works
Self-citationHu, K., Wang, D. G., Liu, P. F., Cao, Y. W., Wang, Y. H., Yang, X. C., Hu, C., Sun, L. J., & Niu, H. T. (2016) · Oncology Reports · doi:10.3892/or.2016.4884 · Cited by 33 · see citing works
Chang, T.-Y., Tsai, W.-C., Huang, T.-S., Su, S., Chang, C.-Y., Ma, H.-Y., Wu, C., Yang, C., Lin, C.-H., Huang, P.-H., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181562 · Cited by 32 · see citing works
Richards, M., Hetheridge, C., & Mellor, H. (2015) · Current Biology · doi:10.1016/j.cub.2015.07.045 · Cited by 31 · see citing works
Targeted Therapy for Breast Cancer Stem Cells by Liposomal Delivery of siRNA against Fibronectin EDB
Sun, Y., Kim, H. S., Saw, P. E., Jon, S., & Moon, W. K. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500190 · Cited by 30 · see citing works
Self-citationSobalska-Kwapis, M., Smolarz, B., Słomka, M., Szaflik, T., Kępka, E., Kulig, B., Siewierska-Górska, A., Polak, G., Romanowicz, H., Strapagiel, D., et al. (2017) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2017.08.037 · Cited by 29 · see citing works
Guo, Y., Niu, B., Song, Q., Zhao, Y., Bao, Y., Tan, S., Si, L., & Zhang, Z. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb00055j · Cited by 29 · see citing works
Small GTPases orchestrate cell-cell communication during collective cell movement
Combedazou, A., Gayral, S., Colombié, N., Fougerat, A., Laffargue, M., & Ramel, D. (2017) · Small GTPases · doi:10.1080/21541248.2017.1366965 · Cited by 28 · see citing works
Lee, J., Kim, C., Yang, H., Park, I., Oh, N., Hua, S. S., Jeong, H., An, H. J., Kim, S. C., Lee, G. M., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0968-t · Cited by 28 · see citing works
Self-citationPopławski, P., Alseekh, S., Jankowska, U., Skupień-Rabian, B., Iwanicka‐Nowicka, R., Kossowska, H., Fogtman, A., Rybicka, B., Bogusławska, J., Adamiok‐Ostrowska, A., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-022-02845-y · Cited by 27 · see citing works
Choi, Y. S., Jang, H., Gupta, B., Jeong, J.-H., Ge, Y., Yong, C. S., Kim, J. O., Bae, J., Song, I., Kim, I., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00952-9 · Cited by 26 · see citing works
Self-citationWang, M., Jiang, X., Yang, Y., Chen, H., Zhang, C., Xu, H., Qi, B., Yao, C., & Xia, H. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00910-w · Cited by 25 · see citing works
The RhoJ-BAD signaling network: An Achilles’ heel for BRAF mutant melanomas
Ruiz, R., Jahid, S., Harris, M. L., Marzese, D. M., Espitia, F., Vasudeva, P., Chen, C., de Feraudy, S. M., Wu, J., Gillen, D. L., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006913 · Cited by 25 · see citing works
Chen, J., Bu, C., Lu, Y., Peng, X., Yu, J., Ding, X., Yuan, P., & Hong, S. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123100 · Cited by 25 · see citing works
Rho GTPases in Retinal Vascular Diseases
Uemura, A., & Fukushima, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073684 · Cited by 23 · see citing works
Self-citationSingh, B. N., Sierra-Pagán, J. E., Gong, W., Das, S., Theisen, J. W. M., Skie, E., Garry, M. G., & Garry, D. J. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314488 · Cited by 23 · see citing works
Tagashira, T., Fukuda, T., Miyata, M., Nakamura, K., Fujita, H., Takai, Y., Hirata, K., & Rikitake, Y. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310991 · Cited by 22 · see citing works
Smolarz, B., Szyłło, K., & Romanowicz, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218235 · Cited by 23 · see citing works
Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis
Kim, C., Yang, H., Park, I., Chon, H. J., Kim, J. H., Kwon, W. S., Lee, W. S., Kim, T. S., & Rha, S. Y. (2016) · Journal of Cancer · doi:10.7150/jca.15578 · Cited by 22 · see citing works
Self-citationStructure-based design of CDC42 effector interaction inhibitors for the treatment of cancer
Jahid, S., Ortega, J. A., Vuong, L. M., Acquistapace, I. M., Hachey, S. J., Flesher, J. L., La Serra, M. A., Brindani, N., La Sala, G., Manigrasso, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110641 · Cited by 21 · see citing works
Ma, J., Zhang, L., Zhang, X., Zhang, L., Zhang, H., Zhu, Y., Huang, X., Zhang, T., Tang, X., Wang, Y., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado5266 · Cited by 21 · see citing works
Go, E., Yang, H., Park, W., Lee, S. J., Han, J., Kong, S. J., Lee, W. S., Han, D. K., Chon, H. J., & Kim, C. (2023) · Small · doi:10.1002/smll.202300544 · Cited by 21 · see citing works
Self-citationRhoJ promotes hypoxia induced endothelial‐to‐mesenchymal transition by activating WDR5 expression
Liu, L., Chen, J., Sun, L., & Xu, Y. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26505 · Cited by 21 · see citing works
Zhang, H., Ren, Y., Hou, L., Chang, J., Zhang, Z., & Zhang, H. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b22412 · Cited by 21 · see citing works
Cervantes‐Villagrana, R. D., García‐Jiménez, I., & Vázquez‐Prado, J. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110749 · Cited by 20 · see citing works
Wang, D., Xing, C., Liang, Y., Wang, C., Zhao, P., Liang, X. H., Li, Q., & Yuan, L. (2024) · Advanced Materials · doi:10.1002/adma.202310421 · Cited by 20 · see citing works
The Adhesome Network: Key Components Shaping the Tumour Stroma
Nikolopoulou, P., Koufaki, M. A., & Kostourou, V. (2021) · Cancers · doi:10.3390/cancers13030525 · Cited by 21 · see citing works
Brindani, N., Vuong, L. M., Acquistapace, I. M., Serra, M. A. L., Ortega, J. A., Veronesi, M., Bertozzi, S. M., Summa, M., Girotto, S., Bertorelli, R., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00276 · Cited by 18 · see citing works
Huang, C., Ciou, J.-S., Chen, S.-T., Kok, V. C., Chung, Y., Tsai, J. J. P., Kurubanjerdjit, N., Huang, C. F., & Ng, K. (2016) · PeerJ · doi:10.7717/peerj.2478 · Cited by 19 · see citing works
Chen, B., Fan, Z., Sun, L., Chen, J., Feng, Y., Fan, X., & Xu, Y. (2020) · Oncogenesis · doi:10.1038/s41389-020-00269-9 · Cited by 18 · see citing works
Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Tuli, H. S., Aggarwal, V., Parashar, G., Aggarwal, D., Parashar, N. C., Tuorkey, M. J., Varol, M., Sak, K., Kumar, M., & Buttar, H. S. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210223095021 · Cited by 18 · see citing works
The Role of RhoJ in Endothelial Cell Biology and Tumor Pathology
Shi, T., Li, G., & Xiao, H. (2016) · BioMed Research International · doi:10.1155/2016/6386412 · Cited by 18 · see citing works
A functional antagonism between RhoJ and Cdc42 regulates fibronectin remodelling during angiogenesis
Sundararaman, A., & Mellor, H. (2020) · Small GTPases · doi:10.1080/21541248.2020.1809927 · Cited by 18 · see citing works
Activation of TC10-Like Transcription by Lysine Demethylase KDM4B in Colorectal Cancer Cells
Chen, B., Zhu, Y., Chen, J., Feng, Y., & Xu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.617549 · Cited by 17 · see citing works
Gugnoni, M., Manzotti, G., Vitale, E., Sauta, E., Torricelli, F., Reggiani, F., Pistoni, M., Piana, S., & Ciarrocchi, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02316-2 · Cited by 16 · see citing works
Yu, M., Yao, H., Zhuo, H., & Zhang, S. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2399 · Cited by 16 · see citing works
Zhang, F., Cui, J. W., Zhang, Y., Yan, M., Wu, X., Liu, X., Yan, D., Zhang, Z., Han, T., Tan, H. F., et al. (2024) · Advanced Science · doi:10.1002/advs.202302713 · Cited by 15 · see citing works
Cervantes‐Villagrana, R. D., Color-Aparicio, V. M., Reyes‐Cruz, G., & Vázquez‐Prado, J. (2019) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-018-00502-6 · Cited by 15 · see citing works
Hong, H. K., Park, Y. J., Kim, D. K., Ryoo, N.-K., Ko, Y.-J., Park, K. H., Kim, H. M., & Woo, S. J. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.13.22 · Cited by 15 · see citing works
Nozaki, M., & Nishizuka, M. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.06.004 · Cited by 14 · see citing works
Franzini, A., Baty, F., Macovei, I. I., Dürr, O., Droege, C., Betticher, D. C., Grigoriu, B. D., Klingbiel, D., Zappa, F., & Brutsche, M. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3135 · Cited by 14 · see citing works
Amaya, C. N., Mitchell, D., & Bryan, B. A. (2017) · BMC Cancer · doi:10.1186/s12885-017-3470-7 · Cited by 14 · see citing works
Zheng, S., Feng, L., Zhang, M., Mu, N., Ge, X., & Fu, J. (2019) · PubMed Central · Cited by 13 · see citing works
Zankov, D. P., & Ogita, H. (2015) · BioMed Research International · doi:10.1155/2015/314178 · Cited by 13 · see citing works
Bacterial particles retard tumor growth as a novel vascular disrupting agent
Guo, F., Ji, G., Li, Q., Yang, Y., Shui, L., Shen, Y., & Yang, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109757 · Cited by 12 · see citing works
Self-citationYue, H., & Lü, X. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023046 · Cited by 11 · see citing works
A Protective Role for RHOJ in NonSmall Cell Lung Cancer Based on Integrated Bioinformatics Analysis
Zeng, T., Chen, C., Yang, P., Zuo, W., Liu, X., & Zhang, Y. (2019) · Journal of Computational Biology · doi:10.1089/cmb.2019.0209 · Cited by 10 · see citing works
Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis
Otálora-Otálora, B. A., Osuna-Garzón, D. A., Carvajal-Parra, M. S., Cañas, A., Montecino, M. A., López-Kleine, L., & Rojas, A. P. (2022) · Biology · doi:10.3390/biology11071082 · Cited by 10 · see citing works
Wang, Y.-F., Duo, D., Yan, Y., He, R., Wang, S., Wang, A., & Wu, X. (2020) · Pharmaceutical Biology · doi:10.1080/13880209.2020.1762668 · Cited by 8 · see citing works
RhoJ: an emerging biomarker and target in cancer research and treatment
Shen, J., Su, X., Wang, S., Wang, Z., Zhong, C., Huang, Y., & Duan, S. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00792-6 · Cited by 8 · see citing works
Ackermann, K. L., Gee, R. R. F., Reyes, S. S., Tader, B. R., & Hamann, M. J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.750026 · Cited by 8 · see citing works
- Authors
- Kim, C., Yang, H., Fukushima, Y., Saw, P. E., Lee, J., Park, J.-S., Park, I., Jung, J., Kataoka, H., Lee, D., Do Heo, W., Kim, I., Jon, S., Adams, R. H., Nishikawa, S.-I., Uemura, A., & Koh, G. Y.
- Affiliations
- Korea Advanced Institute of Science and Technology (KR)
- Kobe University (JP)
- RIKEN (JP)
- Max Planck Institute for Molecular Biomedicine (DE)
- Corresponding author
- Uemura, Akiyoshi
- Koh, Gou Young
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 25
- Issue
- 1
- Pages
- 102-117
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2068757005
- Cited by
- 131
- References
- 44
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 10 · 2023: 15 · 2022: 7 · 2021: 12 · 2020: 19 · 2019: 12 · 2018: 7 · 2017: 13 · 2016: 12 · 2015: 8 · 2014: 5
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- RhoJ, Rho GTPases, tumor angiogenesis, vascular disruption, tumor vasculature, RhoA/ROCK signaling, Rho kinase, tumor endothelial cells, anti-angiogenic therapy, combination therapy, chemotherapy, vascular disrupting agents, tumor progression
- MeSH terms
- Animals, Humans, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Experimental, Neovascularization, Pathologic, Signal Transduction, Angiogenesis Inhibitors, GTP Phosphohydrolases, rho GTP-Binding Proteins, rhoA GTP-Binding Protein, RNA, Small Interfering, Mice, rho-Associated Kinases, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
